医学
杜瓦卢马布
内科学
实体瘤疗效评价标准
不利影响
放射外科
免疫疗法
肿瘤科
进行性疾病
放射治疗
无容量
胰腺癌
外科
胃肠病学
癌症
化疗
泌尿科
作者
Changqing Xie,Austin G. Duffy,Gagandeep Singh Brar,Suzanne Fioravanti,Donna Mabry‐Hrones,Melissa Walker,Cecilia Monge Bonilla,Bradford J. Wood,Deborah E. Citrin,Elizabeth M. Gil Ramirez,Freddy E. Escorcia,Bernadette A. Redd,Jonathan Matthew Hernandez,Jeremy L. Davis,Billel Gasmi,David Erwin Kleiner,Seth M. Steinberg,Jennifer Clare Jones,Tim F. Greten
标识
DOI:10.1158/1078-0432.ccr-19-3624
摘要
PURPOSE: The effectiveness of immune checkpoint inhibitors (ICI) is limited in pancreatic ductal adenocarcinoma (PDAC). We conducted a phase I study to evaluate the safety of ICI with stereotactic body radiation therapy (SBRT) in patients with metastatic PDAC. PATIENTS AND METHODS: Patients enrolled must have received at least one line of prior systemic chemotherapy for metastatic disease. Cohorts A1 and A2 received durvalumab every 2 weeks plus either 8 Gy in one fraction of SBRT on day 1 or 25 Gy in five fractions on day -3 to +1. Cohorts B1 and B2 received durvalumab plus tremelimumab every 4 weeks and either 8 Gy in one fraction of SBRT on day 1 or 25 Gy in five fractions on day -3 to +1. ICIs were continued until unacceptable toxicity or disease progression. The primary objective was the safety and feasibility of treatment. Objective response was assessed in lesions not subjected to SBRT. RESULTS: Fifty-nine patients were enrolled and 39 were evaluable for efficacy. No dose-limiting toxicities were seen. The most common adverse event was lymphopenia. Two patients achieved a partial response (one confirmed and the other unconfirmed). The overall response rate was 5.1%. Median PFS and OS was 1.7 months [95% confidence intervals (CI), 0.8-2.0 months] and 3.3 months (95% CI, 1.2-6.6 months) in cohort A1; 2.5 months (95% CI, 0.1-3.7 months) and 9.0 months (95% CI, 0.5-18.4 months) in A2; 0.9 months (95% CI, 0.7-2.1 months) and 2.1 months (95% CI, 1.1-4.3 months) in B1; and 2.3 months (95% CI, 1.9-3.4 months) and 4.2 months (95% CI, 2.9-9.3 months) in B2. CONCLUSIONS: The combination of ICI and SBRT has an acceptable safety profile and demonstrates a modest treatment benefit in patients with metastatic PDAC.
科研通智能强力驱动
Strongly Powered by AbleSci AI